169 related articles for article (PubMed ID: 36976781)
21. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the Cumulative Live Birth Rates of Progestin-Primed Ovarian Stimulation and Flexible GnRH Antagonist Protocols in Patients With Low Prognosis.
Du M; Zhang J; Li Z; Liu X; Li J; Liu W; Guan Y
Front Endocrinol (Lausanne); 2021; 12():705264. PubMed ID: 34589055
[TBL] [Abstract][Full Text] [Related]
23. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
[TBL] [Abstract][Full Text] [Related]
24. Progestin-Primed Ovarian Stimulation Versus Mild Stimulation Protocol in Advanced Age Women With Diminished Ovarian Reserve Undergoing Their First
Tu X; You B; Jing M; Lin C; Zhang R
Front Endocrinol (Lausanne); 2021; 12():801026. PubMed ID: 35140685
[TBL] [Abstract][Full Text] [Related]
25. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve.
Turkgeldi E; Yildiz S; Cekic SG; Shakerian B; Keles I; Ata B
Hum Fertil (Camb); 2022 Apr; 25(2):306-312. PubMed ID: 32672129
[TBL] [Abstract][Full Text] [Related]
27. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
[TBL] [Abstract][Full Text] [Related]
28. Suboptimal response to GnRH-agonist trigger during oocyte cryopreservation: a case series.
Russo M; Liu K; Chan C
Reprod Biol Endocrinol; 2020 Jun; 18(1):59. PubMed ID: 32503566
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Dydrogesterone and Medroxyprogesterone in the Progestin-Primed Ovarian Stimulation Protocol for Patients With Poor Ovarian Response.
Zhang J; Du M; Li Z; Liu W; Ren B; Zhang Y; Guan Y
Front Endocrinol (Lausanne); 2021; 12():708704. PubMed ID: 34630325
[TBL] [Abstract][Full Text] [Related]
30. IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients.
Esmaeilian Y; Hela F; Bildik G; Akin N; İltumur E; Yusufoglu S; Yildiz CS; Keles İ; Vatansever D; Taskiran C; Yakin K; Oktem O
Hum Reprod; 2023 Jan; 38(1):113-124. PubMed ID: 36367834
[TBL] [Abstract][Full Text] [Related]
31. Dual trigger with the combination of gonadotropin-releasing hormone agonist and standard dose of human chorionic gonadotropin improves
Mutlu I; Demirdag E; Cevher F; Erdem A; Erdem M
J Obstet Gynaecol; 2022 Jul; 42(5):1239-1244. PubMed ID: 34565274
[TBL] [Abstract][Full Text] [Related]
32. Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases.
Saito S; Yamada M; Yano R; Takahashi K; Ebara A; Sakanaka H; Matsumoto M; Ishimaru T; Utsuno H; Matsuzawa Y; Ooka R; Fukuoka M; Akashi K; Kamijo S; Hamatani T; Tanaka M
J Ovarian Res; 2023 Aug; 16(1):159. PubMed ID: 37563616
[TBL] [Abstract][Full Text] [Related]
33. Progestin-primed ovarian stimulation versus GnRH antagonist protocol in poor responders: Risk of premature LH surge and outcome of oocyte retrieval.
Kao TC; Hsieh YC; Yang IJ; Wu MY; Chen MJ; Yang JH; Chen SU
J Formos Med Assoc; 2023 Jan; 122(1):29-35. PubMed ID: 36123235
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Cumulative Live Birth Rates Between GnRH-A and PPOS in Low-Prognosis Patients According to POSEIDON Criteria: A Cohort Study.
Zhang S; Yin Y; Li Q; Zhang C
Front Endocrinol (Lausanne); 2021; 12():644456. PubMed ID: 34234739
[TBL] [Abstract][Full Text] [Related]
35. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Protocols of Controlled Ovarian Stimulation in Obtaining Mature Oocytes (MII): Retrospective Study on Assisted Reproductive Technology Procedures.
Martins CMRB; Ruivo PCPFGC; Vaz-Oliani DCM; Martins RAS; Oliani AH
JBRA Assist Reprod; 2022 Aug; 26(3):387-397. PubMed ID: 34786902
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the cumulative live birth rates after 1 in vitro fertilization cycle in women using gonadotropin-releasing hormone antagonist protocol vs. progestin-primed ovarian stimulation: a propensity score-matched study.
Chen H; Teng XM; Sun ZL; Yao D; Wang Z; Chen ZQ
Fertil Steril; 2022 Oct; 118(4):701-712. PubMed ID: 35940929
[TBL] [Abstract][Full Text] [Related]
38. Dual Triggering With Gonadotropin-Releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate.
Fabris AM; Cruz M; Legidos V; Iglesias C; Muñoz M; García-Velasco JA
Reprod Sci; 2017 Aug; 24(8):1221-1225. PubMed ID: 28715965
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
[TBL] [Abstract][Full Text] [Related]
40. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
